Annexon Biosciences is a clinical-stage biopharmaceutical company that develops novel therapies for autoimmune and neurodegenerative diseases, including ophthalmic diseases. It is pioneering the treatment of classical complement-mediated autoimmune and neurodegenerative diseases.
The company's product candidates are designed to block C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its pipeline is based on its platform technology that is addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q.
The company comprises of a leadership team that has a track-record of discovering, developing and commercializing breakthrough therapeutics for the disease indications. The company is committed to leveraging its platform's technology to develop novel C1q inhibitors for treating patients with antibody-mediated autoimmune and complement-mediated neurodegenerative diseases.
